KaliVir Immunotherapeutics: Series ADevelops oncolytic immunotherapies for patients with advanced solid tumorsOct 4, 2026RoundOSKaliVir ImmunotherapeuticsCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesHealthtechNorth AmericaSeries A